Table 2 Demographic Characteristics of the Participants of the surveillance strategy implemented by the Ministry of Health of the Province of Buenos Aires that were boosted with BNT162b2 at Enrolment

From: Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults

Variable

No. of participants

18

Sex

Male (N (%))

5 (27.8)

Female (N (%))

13 (72.2)

Age (Median (IQRa))

36.5 (32–45)

COVID-19 Primary Vaccine Platform

BBIBP-CorV (N (%))

2 (11.1)

Sputnik V (rAd26/rAd5) (N (%))

16 (88.9)

Time since last dose of primary immunization schedule (in months, (Median (IQR))

4.2 (3.8–4.6)

Prior COVID-19b

No (N (%))

18 (100.0)

Yes (N (%))

0 (0.0)

Seropositive for N (SARS-CoV-2 nucleoprotein)-specific IgG

No (N (%))

9 (50.0)

Yes (N (%))

9 (50.0)

  1. aIQR Interquartile range.
  2. bConfirmed diagnostic of COVID-19 (PCR, Antigen test or by epidemiological diagnostic).